title: Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate.
abstract: Imatinib has shown unprecendeted success in the treatment of chronic myeloid leukemia (CML). However, over few years there have been reports regarding the primary and secondary resistance to Imatinib dampening the overall outcome in CML patients. In this study we have tried to assess the effect of dose escalation in patients resistant to standard dose of Imatinib and correlate it with presence of ABL kinase domain (KD) mutations. There were 90 patients resistant to imatinib, out which 29 patients were identified with KD mutations. The most common mutation was T315I , 9 out of 29 patients had it. 35 (38%) responded to dose escalation and had 67% event free survival (EFS) at estimated 2 years. Our results showed that dose escalation can over come resistance in some patients especially those in cytogenetic failure.
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Senthil
authors: S
authors: Rajappa
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Krishna Mohan
authors: KM
authors: Mallavarapu
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Sadashivudu
authors: S
authors: Gundeti
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Tara Roshni
authors: TR
authors: Paul
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Rachel Thomas
authors: RT
authors: Jacob
authors: Nizam's Institute of Medical Science is a Premier Institute, Hyderabad, Andhra Pradesh, India.
authors: Raghunadharao
authors: R
authors: Digumarti
keywords: Chronic myeloid leukemia; imatinib; kinase domain mutations and responses